In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From WuXi AppTec

Hidden Dragon? Investors Return To New China Biotech Reality

Several Chinese biotech developments during the Lunar New Year break have put investors on high alert, namely the continued share price slide of Chinese biotech bellwether WuXi Apptec, Lianbio ceasing operations and I-Mab divesting its China business to become a fully US-focused company.

China Business Strategies

US Draft Bill Highlights Perceived China Biotech Threat

A draft bill from the US House related to national security issues sent WuXi Biologics' shares tumbling over concerns around increased US scrutiny of Chinese firms, which a company clarification did little to dispel.  

China United States

Late To The Antibody-Drug Conjugate Party, But Will 2024 Be A Turning Point For India?

In 2024, Sun Pharma’s ADC candidate is expected to be in human trials, while CDMOs like Piramal Pharma Solutions and Aurigene are to operationalize significant new capacities. But can India compensate for a late start on the ADC journey by tapping low development costs and favorable policies, or is it too little with China far ahead in the race?

Research & Development Business Strategies

What’s In Store For CROs, CDMOs – “Stay In Your Swim Lane”, Consolidation, Divestitures

Brian Scanlan, operating partner (life sciences), Edgewater Capital Partners, in an interview with Scrip, outlines where things may be headed in the CRO/CDMO segment amid big pharma streamlining efforts, “belt tightening” by emerging biopharma, down rounds and heightened geopolitical tension.

Commercial Financing
See All

Company Information

  • Industry
  • Contract Research Organization-CRO
  • Laboratory Testing Services
  • Medical Devices
  • Pharmaceuticals
  • Services
  • Biotechnology
    • Drug Discovery Technologies
      • ADMET
      • Bioinformatics
  • Other Names / Subsidiaries
    • Crelux GmbH
    • Faxian Therapeutics
    • JW Biotechnology (Shanghai) Co., Ltd
    • OXGENE
    • ResearchPoint Global
    • STA Pharmaceutical Co., Ltd.
    • WuXi PharmaTech
    • WuXi Merger Limited
    • XenoBiotic Laboratories, Inc.
UsernamePublicRestriction

Register